Evolution and improved outcomes in the era of multimodality treatment for extended pancreatectomy.

IF 3.5 3区 医学 Q1 SURGERY BJS Open Pub Date : 2024-07-02 DOI:10.1093/bjsopen/zrae065
Vikram A Chaudhari, Aditya R Kunte, Amit N Chopde, Vikas Ostwal, Anant Ramaswamy, Reena Engineer, Prabhat Bhargava, Munita Bal, Nitin Shetty, Suyash Kulkarni, Shraddha Patkar, Manish S Bhandare, Shailesh V Shrikhande
{"title":"Evolution and improved outcomes in the era of multimodality treatment for extended pancreatectomy.","authors":"Vikram A Chaudhari, Aditya R Kunte, Amit N Chopde, Vikas Ostwal, Anant Ramaswamy, Reena Engineer, Prabhat Bhargava, Munita Bal, Nitin Shetty, Suyash Kulkarni, Shraddha Patkar, Manish S Bhandare, Shailesh V Shrikhande","doi":"10.1093/bjsopen/zrae065","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The evolution and outcomes of extended pancreatectomies at a single institute over 15 years are presented in this study.</p><p><strong>Methods: </strong>A retrospective analysis of the institutional database was performed from 2015 to 2022 (period B). Patients undergoing extended pancreatic resections, as defined by the International Study Group for Pancreatic Surgery, were included. Perioperative and survival outcomes were compared with data from 2007-2015 (period A). Regression analyses were used to identify factors affecting postoperative and long-term survival outcomes.</p><p><strong>Results: </strong>A total of 197 (16.1%) patients underwent an extended resection in period B compared to 63 (9.2%) in period A. Higher proportions of borderline resectable (5 (18.5%) versus 51 (47.7%), P = 0.011) and locally advanced tumours (1 (3.7%) versus 24 (22.4%), P < 0.001) were resected in period B with more frequent use of neoadjuvant therapy (6 (22.2%) versus 79 (73.8%), P < 0.001). Perioperative mortality (4 (6.0%) versus 12 (6.1%), P = 0.81) and morbidity (23 (36.5%) versus 83 (42.1%), P = 0.57) rates were comparable. The overall survival for patients with pancreatic adenocarcinoma was similar in both periods (17.5 (95% c.i. 6.77 to 28.22) versus 18.3 (95% c.i. 7.91 to 28.68) months, P = 0.958). Resectable, node-positive tumours had a longer disease-free survival (DFS) in period B (5.81 (95% c.i. 1.73 to 9.89) versus 14.03 (95% c.i. 5.7 to 22.35) months, P = 0.018).</p><p><strong>Conclusion: </strong>Increasingly complex pancreatic resections were performed with consistent perioperative outcomes and improved DFS compared to the earlier period. A graduated approach to escalating surgical complexity, multimodality treatment, and judicious patient selection enables the resection of advanced pancreatic tumours.</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293468/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJS Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjsopen/zrae065","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The evolution and outcomes of extended pancreatectomies at a single institute over 15 years are presented in this study.

Methods: A retrospective analysis of the institutional database was performed from 2015 to 2022 (period B). Patients undergoing extended pancreatic resections, as defined by the International Study Group for Pancreatic Surgery, were included. Perioperative and survival outcomes were compared with data from 2007-2015 (period A). Regression analyses were used to identify factors affecting postoperative and long-term survival outcomes.

Results: A total of 197 (16.1%) patients underwent an extended resection in period B compared to 63 (9.2%) in period A. Higher proportions of borderline resectable (5 (18.5%) versus 51 (47.7%), P = 0.011) and locally advanced tumours (1 (3.7%) versus 24 (22.4%), P < 0.001) were resected in period B with more frequent use of neoadjuvant therapy (6 (22.2%) versus 79 (73.8%), P < 0.001). Perioperative mortality (4 (6.0%) versus 12 (6.1%), P = 0.81) and morbidity (23 (36.5%) versus 83 (42.1%), P = 0.57) rates were comparable. The overall survival for patients with pancreatic adenocarcinoma was similar in both periods (17.5 (95% c.i. 6.77 to 28.22) versus 18.3 (95% c.i. 7.91 to 28.68) months, P = 0.958). Resectable, node-positive tumours had a longer disease-free survival (DFS) in period B (5.81 (95% c.i. 1.73 to 9.89) versus 14.03 (95% c.i. 5.7 to 22.35) months, P = 0.018).

Conclusion: Increasingly complex pancreatic resections were performed with consistent perioperative outcomes and improved DFS compared to the earlier period. A graduated approach to escalating surgical complexity, multimodality treatment, and judicious patient selection enables the resection of advanced pancreatic tumours.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
扩展胰腺切除术多模式治疗时代的演变和更好的疗效。
背景:本研究介绍了 15 年来在一家医院进行的扩大胰腺切除术的演变和结果:本研究介绍了一家医疗机构 15 年来扩大胰腺切除术的演变和结果:对2015年至2022年(B期)的机构数据库进行了回顾性分析。根据国际胰腺外科研究小组的定义,纳入了接受扩大胰腺切除术的患者。围手术期和生存结果与 2007-2015 年(A 阶段)的数据进行了比较。通过回归分析确定影响术后和长期生存结果的因素:B期共有197例(16.1%)患者接受了扩大切除术,而A期为63例(9.2%)。011) 和局部晚期肿瘤(1 (3.7%) 对 24 (22.4%),P < 0.001)的切除率在 B 阶段更高,新辅助治疗的使用也更频繁(6 (22.2%) 对 79 (73.8%),P < 0.001)。围手术期死亡率(4(6.0%)对 12(6.1%),P = 0.81)和发病率(23(36.5%)对 83(42.1%),P = 0.57)相当。两个时期胰腺癌患者的总生存期相似(17.5(95% c.i.6.77至28.22)个月对18.3(95% c.i.7.91至28.68)个月,P = 0.958)。可切除的结节阳性肿瘤在B期的无病生存期(DFS)更长(5.81(95% 置信区间:1.73 至 9.89)个月对 14.03(95% 置信区间:5.7 至 22.35)个月,P = 0.018):结论:胰腺切除术越来越复杂,但围术期疗效一致,DFS较早期有所改善。手术复杂程度的逐步提高、多模式治疗以及对患者的审慎选择使晚期胰腺肿瘤的切除成为可能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BJS Open
BJS Open SURGERY-
CiteScore
6.00
自引率
3.20%
发文量
144
期刊最新文献
Classifying histopathological growth patterns for resected colorectal liver metastasis with a deep learning analysis. Short-term outcomes depending on type of oesophagojejunostomy in laparoscopic total gastrectomy for gastric cancer: retrospective study based on a Korean Nationwide Survey for Gastric Cancer in 2019. Association of postoperative opioid type with mortality and readmission rates: multicentre retrospective cohort study. Effects of the superior mesenteric artery approach versus the no-touch approach during pancreatoduodenectomy on the mobilization of circulating tumour cells and clusters in pancreatic cancer (CETUPANC): randomized clinical trial. Reported outcomes in studies of intermittent claudication - first step toward a core outcome set: systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1